Cytokine therapies for cancer aren’t new but they are attracting renewed interest. Some pharmaceutical companies see drug combinations using cytokines as a way to broaden the reach of immunotherapy, which still doesn’t work for the majority of cancer patients.
This week, Eli Lilly (NYSE: LLY) showed how much it believes in cytokines. The Indianapolis drug maker reached a deal to acquire Armo BioSciences and its pipeline of cytokine therapies for $1.6 billion in cash. The bid follows other moves by venture capitalists and drugmakers to invest in cytokine cancer drugs, perhaps most notably Bristol-Myers Squibb’s decision to shell out $1.85… Read more »
UNDERWRITERS AND PARTNERS